cytarabine has been researched along with pyrazines in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (22.50) | 29.6817 |
| 2010's | 23 (57.50) | 24.3611 |
| 2020's | 8 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abboud, CN; Bechelli, J; Lancet, JE; Liesveld, JL; Lu, C; Phillips, G; Rosell, KE | 1 |
| Baer, MR; Minderman, H; O'Loughlin, KL; Zhou, Y | 1 |
| Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; D'Amato, F; De Angelo, DJ; Galinsky, I; Levine, J; McAfee, S; Miller, KB; Neuberg, D; Schenkein, D; Sirulnik, A; Stone, RM; Supko, JG; Trehu, EG; Wadleigh, M; Zahrieh, D | 1 |
| Drize, N; Nifontova, I; Petrova, T; Svinareva, D | 1 |
| Calliada, F; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P | 1 |
| Bentz, M; Dreyling, M; Hiddemann, W; Jentsch-Ullrich, K; Mueck, R; Rohrberg, R; von Schilling, C; Weidmann, E; Weigert, O | 1 |
| Jin, J; Liu, H; Tong, HY; Wei, JY; Yu, WJ; Zhang, FJ; Zhu, WF | 1 |
| Gu, B; Liu, Y; Qiu, H; Ruan, C; Shi, X; Sun, A; Tang, X; Wu, D; Xue, S; Zhou, H | 1 |
| Bruserud, O; Hatfield, KJ; Kalland, KH; Kittang, AO; Oyan, AM; Reikvam, H | 1 |
| Fayad, LE; Feldman, T; Ford, P; Goldberg, S; Goy, A; Hartig, K; Kwak, LW; McLaughlin, P; Pecora, A; Pro, B; Rodriguez, A; Romaguera, JE; Smith, J; Wang, M; Weaver, P | 1 |
| Alba, L; Antinori, A; Bibas, M; Del Nonno, F; Grisetti, S; Picchi, G | 1 |
| Barbarat, A; Houlgatte, R; Raharijaona, M; Rolland, D; Thieblemont, C | 1 |
| Dreyling, M | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Ades, L; Berger, E; Bordessoule, D; Braun, T; Cahn, JY; Charbonnier, A; Chaury, MP; Cheze, S; Dreyfus, F; Etienne, G; Fenaux, P; Guerci-Bresler, A; Legros, L; Natarajan-Amé, S; Park, S; Ravoet, C; Schmidt, A; Stamatoullas, A; Vey, N | 1 |
| Du, SH; Du, X; He, C; Jia, PM; Tong, JH; Zhou, L | 2 |
| Camara-Clayette, V; Hermine, O; Ribrag, V | 1 |
| Amrein, PC; Attar, EC; Bloomfield, CD; Blum, W; DeAngelo, DJ; Johnson, JL; Kolitz, JE; Larson, RA; Lozanski, G; Marcucci, G; Moser, B; Powell, BL; Stone, RM; Voorhees, P; Wadleigh, M; Wang, ES | 1 |
| Annereau, JP; Bailly, C; Bonnet, D; Brel, V; Créancier, L; Currie, E; Fournier, E; Gomes, B; Guilbaud, N; Guminski, Y; Kruczynski, A; Pillon, A; Vandenberghe, I | 1 |
| El Azeeim, HA; El Husseiny, NM; Kasem, N; Mattar, MW | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM | 1 |
| Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z | 1 |
| Adlard, K; Alonzo, TA; Ballard, J; Gamis, AS; Gerbing, RB; Horton, TM; Howard, DS; Jenkins, G; Kelder, A; Moscow, JA; Perentesis, JP; Schuurhuis, GJ; Smith, FO | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Fiala, MA; Fletcher, T; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wang, TF; Westervelt, P; Wu, N | 1 |
| Campo, E; Rule, S | 1 |
| Barth, MJ; Czuczman, MS; Frys, S; Gu, JJ; Hernandez-Ilizaliturri, FJ; Hu, Q; Mavis, C; Simons, Z; Skitzki, J; Song, L | 1 |
| Tiong, IS; Wei, AH | 1 |
| DiNardo, CD; Wei, AH | 1 |
| Burnett, A; Stone, R | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Bhatnagar, B; Blachly, JS; Blum, WG; Byrd, JC; Crosswell, HE; Lin, TL; Liu, J; Long, L; Mims, AS; Minden, MD; Munugalavadla, V; Oellerich, T; Orwick, S; Pan, Y; Rao, AV; Serve, H; Walker, AR; Zhang, D | 1 |
| Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC | 1 |
| Thol, F | 1 |
| Chen, CY; Cui, ZL; Fu, Y; Gao, ZX; Liu, F; Ma, S; Zhang, L; Zhou, MR | 1 |
| Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I | 1 |
9 review(s) available for cytarabine and pyrazines
| Article | Year |
|---|---|
[Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Ki-1 Antigen; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Precision Medicine; Prognosis; Pyrazines; Risk Factors; Rituximab; Survival Rate; Waldenstrom Macroglobulinemia | 2011 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
Emerging agents for the treatment of mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Molecular Targeted Therapy; Prognosis; Pyrazines; Recurrence; Salvage Therapy; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Watchful Waiting | 2012 |
Mantle cell lymphoma: evolving management strategies.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytarabine; Humans; Lymphoma, Mantle-Cell; Medical Oncology; Mutation; Positron-Emission Tomography; Prognosis; Pyrazines; Rituximab; Treatment Outcome | 2015 |
New drugs creating new challenges in acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration | 2019 |
AML: New Drugs but New Challenges.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrazines | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Topics: Aniline Compounds; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Echinocandins; fms-Like Tyrosine Kinase 3; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Mycoses; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Staurosporine; Triazoles | 2020 |
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
10 trial(s) available for cytarabine and pyrazines
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cohort Studies; Cytarabine; Female; Gene Expression Profiling; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Pyrazines; Tissue Distribution; Treatment Outcome | 2008 |
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Pyrazines; Salvage Therapy; Survival Analysis | 2009 |
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Pyrazines; Rituximab; Vincristine | 2010 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazines; Survival Analysis; Treatment Outcome | 2012 |
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Topics: Aged; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Histocompatibility Antigens Class II; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Nervous System; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous | 2014 |
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Rabbits; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning | 2014 |
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
Topics: Adult; Cytarabine; Daunorubicin; Female; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Indazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloid Ecotropic Viral Integration Site 1 Protein; Pyrazines; Syk Kinase | 2020 |
21 other study(ies) available for cytarabine and pyrazines
| Article | Year |
|---|---|
Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Survival; Coculture Techniques; Cytarabine; Endothelial Cells; Humans; Leukemia, Myeloid, Acute; Proteasome Inhibitors; Pyrazines | 2005 |
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Cytarabine; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Protease Inhibitors; Pyrazines; Tumor Suppressor Protein p53 | 2007 |
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes | 2007 |
Sensitivity of mesenchymal stem cells and their progeny to medicines used for the treatment of hematoproliferative diseases.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Busulfan; Cyclophosphamide; Cytarabine; Female; Fibroblasts; Mesenchymal Stem Cells; Methotrexate; Mice; Mice, Inbred Strains; Pyrazines; Stromal Cells | 2008 |
Infiltration of the spinal cord in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Pyrazines; Spinal Cord Neoplasms | 2008 |
Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Middle Aged; Pancreatic Neoplasms; Plasmacytoma; Pyrazines; Retreatment; Treatment Outcome; Vincristine | 2009 |
Successful bortezomib-based treatment in POEMS syndrome.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Depression, Chemical; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Humans; Male; Melphalan; Plasma Cells; POEMS Syndrome; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; Vascular Endothelial Growth Factor A; Vincristine | 2009 |
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiopoietin-2; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Chemokines; Coculture Techniques; Culture Media, Serum-Free; Cytarabine; Diterpenes; Endothelial Cells; Female; Humans; Imidazoles; Leukemia, Myeloid; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Pyrazines; Quinoxalines; Receptor, TIE-2; Recombinant Proteins; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 2010 |
Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Cytarabine; Deoxycytidine; Dexamethasone; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Lenalidomide; Lymphoma, Large-Cell, Immunoblastic; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Pyrazines; Recombinant Proteins; Thalidomide; Young Adult | 2010 |
Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cytarabine; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione S-Transferase pi; Humans; Lectins; Lymphoma, Mantle-Cell; Pyrazines | 2010 |
[Effect of bortezomib and low concentration cytarabine on apoptosis in U937 cell line].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cytarabine; Humans; Pyrazines; U937 Cells | 2012 |
[Mechanism of apoptosis synergistically induced by bortezomib combined with cytarabine in U937 cell line].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cytarabine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Phosphorylation; Pyrazines; Reactive Oxygen Species; U937 Cells | 2012 |
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cytarabine; Deoxycytidine; Doxorubicin; Fetal Blood; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Podophyllotoxin; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
Multiple myeloma: a descriptive study of 217 Egyptian patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Egypt; Female; Hospitals, Urban; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Retrospective Studies; Severity of Illness Index; Thalidomide; Vincristine | 2014 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cytarabine; Drug Resistance, Neoplasm; Female; G1 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Lymphoma, B-Cell; Male; Mice; Mice, SCID; Pyrazines; Pyridines; Rituximab; Xenograft Model Antitumor Assays | 2015 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
What to use to treat AML: the role of emerging therapies.
Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines | 2021 |
The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytarabine; Diamines; Leukemia, Myeloid, Acute; Mice; Oxadiazoles; Pyrazines; Reactive Oxygen Species | 2022 |